CONKO-003

NCT00786058 📎

Regimen

Experimental
OFF regimen: oxaliplatin 85 mg/m2 d8, 22 + leucovorin 200 mg/m2 + 5-FU 2000 mg/m2 24h infusion d1, 8, 15, 22 q6w.
Control
FF (folinic acid + 5-FU) alone, without oxaliplatin.

Population

Advanced PDAC with progression on prior gemcitabine, ECOG 0-2, German multicenter.

Key finding

CONKO-003 showed addition of oxaliplatin to 5-FU/FA improves OS in gemcitabine-refractory advanced PDAC by ~2.6 months. Established oxaliplatin-based regimens (OFF, later FOLFOX) as a viable 2L choice — though contradicted by PANCREOX. Never FDA-labeled but NCCN-recognized.

Source: PMID 24982456

Timeline

    Guideline citations

    • NCCN PANCREATIC (p.97)